Gan and Lee - Public Comps and Valuation Multiples

Gan and Lee Overview

About Gan and Lee

Gan and Lee Pharmaceuticals is engaged in Research, development, production and sales of recombinant insulin analog APIs and injections.

Founded

1998

HQ

Employees

n/a

Website

ganlee.com.cn

Sectors

Biopharmaceuticals
Drug Development & Therapeutics
BioTech

Financials

LTM Revenue $562M

LTM EBITDA $179M

EV

$6.1B

Valuation Multiples

Multiples.vc

Valuation Multiples for 15K+ Public Comps

Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.

Browse Valuation Multiples

Gan and Lee Financials

As of September 2025, Gan and Lee reported last 12-month revenue of $562M and EBITDA of $179M.

In the same period, Gan and Lee generated $433M in LTM gross profit and $143M in net income.

See Gan and Lee valuation multiples based on analyst estimates

Gan and Lee P&L

In the most recent fiscal year, Gan and Lee reported revenue of $428M and EBITDA of $125M.

Gan and Lee expects next 12-month revenue of XXX and NTM EBITDA of XXX

See Gan and Lee valuation multiples based on analyst estimates

	LTM	NTM	Last FY	FY 2025	FY 2026	FY 2027
Revenue	$562M	XXX	$428M	XXX	XXX	XXX
Gross Profit	$433M	XXX	$320M	XXX	XXX	XXX
Gross Margin	77%	XXX	75%	XXX	XXX	XXX
EBITDA	$179M	XXX	$125M	XXX	XXX	XXX
EBITDA Margin	32%	XXX	29%	XXX	XXX	XXX
EBIT	$143M	XXX	$43.7M	XXX	XXX	XXX
EBIT Margin	26%	XXX	10%	XXX	XXX	XXX
Net Profit	$143M	XXX	$86.3M	XXX	XXX	XXX
Net Margin	25%	XXX	20%	XXX	XXX	XXX
Net Debt	XXX	XXX	n/a	XXX	XXX	XXX

Financial data powered by Morningstar, Inc.

.seo-only-financials-wrapper { position: static; left: auto; width: auto; height: auto; overflow: visible; }

Financial performance metrics for Gan and Lee including revenue, profitability, and margin analysis across different time periods. The company reported last twelve months revenue of $562M. EBITDA for the last twelve months was $179M. In the most recent fiscal year, Gan and Lee achieved $428M in revenue and $125M in EBITDA.
Financial Metric	Last Twelve Months (LTM)	Next Twelve Months (NTM)	Most Recent Fiscal Year	Current Fiscal Year (2025)	Next Fiscal Year (2026)	Two Years Forward (2027)
Total Revenue	$562M	Analyst estimates available to subscribers	$428M	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
Gross Profit	$433M	Analyst estimates available to subscribers	$320M	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
Gross Profit Margin	77.1% gross margin	Analyst estimates available to subscribers	74.8% gross profit margin	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
EBITDA (Earnings Before Interest, Taxes, Depreciation, Amortization)	$179M	Analyst estimates available to subscribers	$125M	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
EBITDA Margin	31.9% EBITDA margin	Analyst estimates available to subscribers	29.2% EBITDA margin	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
EBIT (Earnings Before Interest and Taxes)	$143M	Analyst estimates available to subscribers	$43.7M	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
EBIT Margin	25.5% EBIT margin	Analyst estimates available to subscribers	10.2% EBIT margin	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
Net Income (Net Profit)	$143M	Analyst estimates available to subscribers	$86.3M	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
Net Profit Margin	25.5% net profit margin	Analyst estimates available to subscribers	20.2% net profit margin	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
Net Debt Position	Detailed debt information available to subscribers	Detailed debt information available to subscribers	n/a	Detailed debt information available to subscribers	Detailed debt information available to subscribers	Detailed debt information available to subscribers

Financial Performance Summary for Gan and Lee

This financial data table provides comprehensive performance metrics for Gan and Lee, a company based in China. The metrics include revenue, profitability measures, and operational efficiency indicators across multiple time periods.

Recent Performance Highlights

Gan and Lee generated $562M in revenue over the last twelve months.
The company achieved $179M in EBITDA over the last twelve months.
Gross profit for the last twelve months was $433M.
Net income over the last twelve months reached $143M.

Fiscal Year Performance

In the most recent fiscal year, Gan and Lee reported $428M in total revenue.
Fiscal year EBITDA was $125M.
The company maintained a gross profit margin of 74.8% in the most recent fiscal year.
EBITDA margin for the fiscal year was 29.2%.
Net profit margin reached 20.2% in the most recent fiscal year.

This financial data is sourced from Morningstar, Inc. and represents the most recent available information for Gan and Lee. Forward-looking estimates and detailed financial projections are available through our premium subscription service.

Gan and Lee Stock Performance

Gan and Lee has current market cap of CNY 45.4B (or $6.4B), and EV of CNY 43.1B (or $6.1B).

Market Cap Evolution

Gan and Lee Stock Data

As of October 7, 2025, Gan and Lee's stock price is CNY 76 (or $11).

See Gan and Lee trading valuation data

EV	Market Cap	Price 1D	Price 1M	Price 3M	Price 12M	EPS
$6.1B	$6.4B	XXX	XXX	XXX	XXX	$0.24

Benchmark Trading Valuation Multiples by Industry

Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more

Start Free Trial

Gan and Lee Valuation Multiples

Gan and Lee's trades at 14.2x EV/Revenue multiple, and 48.6x EV/EBITDA.

See valuation multiples for Gan and Lee and 15K+ public comps

Gan and Lee Financial Valuation Multiples

As of October 7, 2025, Gan and Lee has market cap of $6.4B and EV of $6.1B.

Equity research analysts estimate Gan and Lee's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX

Gan and Lee has a P/E ratio of 44.5x.

	LTM	NTM	Last FY	FY 2025	FY 2026	FY 2027
Market cap (current)	$6.4B	XXX	$6.4B	XXX	XXX	XXX
EV (current)	$6.1B	XXX	$6.1B	XXX	XXX	XXX
EV/Revenue	10.8x	XXX	14.2x	XXX	XXX	XXX
EV/EBITDA	33.8x	XXX	48.6x	XXX	XXX	XXX
EV/EBIT	42.3x	XXX	138.7x	XXX	XXX	XXX
EV/Gross Profit	14.0x	XXX	n/a	XXX	XXX	XXX
P/E	44.5x	XXX	73.8x	XXX	XXX	XXX
EV/FCF	n/a	XXX	446.9x	XXX	XXX	XXX

Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Get Gan and Lee Valuation Multiples

Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.

Start Free Trial

Gan and Lee Margins & Growth Rates

Gan and Lee's last 12 month revenue growth is 25%

Gan and Lee's revenue per employee in the last FY averaged n/a, while opex per employee averaged n/a for the same period.

Gan and Lee's rule of 40 is 45% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).

Gan and Lee's rule of X is 93% (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).

See operational valuation multiples for Gan and Lee and other 15K+ public comps

Gan and Lee Operational Valuation Multiples

	LTM	NTM	Last FY	FY 2025	FY 2026	FY 2027
Revenue Growth	25%	XXX	31%	XXX	XXX	XXX
EBITDA Margin	32%	XXX	29%	XXX	XXX	XXX
EBITDA Growth	39%	XXX	68%	XXX	XXX	XXX
Rule of 40	45%	XXX	54%	XXX	XXX	XXX
Bessemer Rule of X	XXX	XXX	93%	XXX	XXX	XXX
Revenue per Employee	XXX	XXX	n/a	XXX	XXX	XXX
Opex per Employee	XXX	XXX	n/a	XXX	XXX	XXX
S&M Expenses to Revenue	XXX	XXX	24%	XXX	XXX	XXX
G&A Expenses to Revenue	XXX	XXX	n/a	XXX	XXX	XXX
R&D Expenses to Revenue	XXX	XXX	18%	XXX	XXX	XXX
Opex to Revenue	XXX	XXX	65%	XXX	XXX	XXX

Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Valuation Multiples Across 220+ Verticals

Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!

Digital Therapeutics

Pharma Analytics

Private Equity

ERP Software

Developer Tools

Consumer SaaS

Streaming Platforms

Explore Valuation Multiples by Industry

Start Free Trial